Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS

NCT04569227 is registered in ClinicalTrials.gov with Enzychem Lifesciences Corporation as lead sponsor.

NCT NCT04569227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04569227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS
Lead sponsor
Enzychem Lifesciences Corporation
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2021
Completion date
November 30, 2021
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19 pneumonia